« Back
Home /
Protein Kinase C (19-31) (TFA)

Protein Kinase C (19-31) (TFA)

Item no.	HY-P1746A-1ea
Manufacturer	MedChem Express
Amount	1 ea
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Formula	C69H119F3N26O18
Citations	[1]Mellor H, et al. The extended protein kinase C superfamily. Biochem J. 1998 Jun 1;332 ( Pt 2):281-92.<br>[2]Nishizuka Y (1995). Protein kinase C and lipid signaling for sustained cellular responses" (abstract). FASEB J. 9 (7): 484–96.
Smiles	OC(C(F)(F)F)=O.CC(C)[C@@H](C(O)=O)NC([C@H](CC(N)=O)NC([C@H](CCCCN)NC([C@H](CCC(N)=O)NC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@H](C)NC(CNC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)NC([C@H](C)NC([C@@H](NC([C@@H](N)CCCNC(N)=N)=O)CC1=CC=CC=C1)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	PKC (19-31) (TFA)
Available
Product Description	Protein Kinase C (19-31) TFA, a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31), is used as protein kinase C substrate peptide for testing the protein kinase C activity[1][2].
Shipping	Room temperature
Manufacturers Applications	COVID-19-immunoregulation
MolecularWeight	1543.82 (free acid)
Clinical_Information	No Development Reported
Manufacturers Research_Area	Inflammation/Immunology
Solubility	H2O
Manufacturers Target	PKC
Pathway	Epigenetics; TGF-beta/Smad
Manufacturers Product type	Peptides

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 1 ea

available

Request delivery time